MARKET COMPOSITE
PSNL - Personalis Inc8:00:00 PM 3/28/2024
Price
$1.49
+ 0.04 (2.76%)
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. Personalis, Inc. has partnership with Berry Genomics. The company was founded in 2011 and is headquartered in Menlo Park, California.
Financials
Quarterly financials
(USD)Dec 2023Q/Q
Revenue19.7MM+8%
Gross Profit5.2MM-
Cost Of Revenue14.5MM-2%
Operating Income-24MM-22%
Operating Expenses29.2MM-
Net Income-26.6MM-9%
R&D13.6MM-19%
G&A11.5MM-4%
Interest Expense9K-40%
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    FREMONT, Calif., March 28, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time.

    FREMONT, Calif., March 28, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California, April 5-10, 2024.

    FREMONT, Calif., March 26, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay. NeXT Personal is designed to help detect minimal residual disease (MRD), monitor therapy response, and identify recurrence with high analytical sensitivity and accuracy, enhancing the decision-making process and ultimately improv

    FREMONT, Calif., March 19, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on November 15, 2023 and March 15, 2024, non-qualified stock options to purchase an aggregate of 41,500 shares of its common stock to ten new employees under Personalis’ 2020 Inducement Plan.

    Personalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Call Transcript February 28, 2024 Personalis, Inc. misses on earnings expectations. Reported EPS is $-0.54 EPS, expectations were $-0.53. PSNL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the Personalis […]

    FREMONT, Calif., February 28, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.

    FREMONT, Calif., February 14, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

    FREMONT, Calif., January 31, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor conferences:

    FREMONT, Calif. & SAN DIEGO, January 30, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s cutting-edge epigenomic 5-hydroxymethylcytosine (5hmC) platform.

    FREMONT, Calif., January 16, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay, providing access for the nation’s 66 million Medicare and Medicare Advantage beneficiaries.